ROLE OF SOME UNCONSERVED RESIDUES IN THE “C” REGION OF THE SKELETAL DHPR II-III LOOP

Angela F. Dulhunty, Yamuna Karunasekara, Suzanne M Curtis, Peta J. Harvey, Philip G. Board and Marco G. Casarotto

Division of Molecular Bioscience, JCSMR and Research School of Chemistry, ANU, Canberra, ACT 2601, Australia

TABLE OF CONTENTS

1. Abstract
2. Introduction
3. Materials and methods
   3.1. Materials
   3.2. Expression of the DHPR II-III loop
   3.3. Single channel measurements
   3.4. Analysis of channel activity
   3.5. Nuclear magnetic resonance (NMR) spectroscopy
   3.6. Statistics
4. Results
   4.1. The recombinant native and mutant DHPR II-III loops
   4.2. Effects of wild type and mutant SDCL on the activity of the skeletal RyR1
   4.3. Effects of the mutant C5 peptides on skeletal RyR.
   4.4. The mutant C5 peptide activates cardiac RyR2 channels
   4.5. Structure of the mutant C5 peptides
5. Discussion
   5.1. Dual actions of both SDCL and CDCL on native skeletal RyRs
   5.2. Changes in the function of the C5 peptides were not correlated with structural changes
   5.3. Comparison with whole cell studies
6. Acknowledgments
7. References

1. ABSTRACT

The actions of the recombinant skeletal dihydropyridine receptor II-III loop (SDCL), and the C region peptide (C5) on native skeletal muscle ryanodine receptor Ca2+ release channel (RyR1) have been examined. Three non conserved residues in the “C” region of the skeletal DHPR II-III loop were replaced by the equivalent cardiac residues in SDCL (A739P, F741T and P742T) and single substitutions made in SDCL (A-P, SDCL-F-T and SDCL-P-T). Wild type SDCL as well as SDCL (A-P, F-T and P-T) activated RyR1 in lipid bilayers with high affinity (10 nM to 1 microM). Wild type SDCL at higher concentrations inhibited RyR1. In contrast, SDCL (A-P, F-T and P-T) inhibited the channels at ≥10 nM. The inhibitory actions of these two skeletal loop mutants were distinctly different from the cardiac II-III loop (CDCL) which, like the wild-type SDCL, activated channels. In contrast to the full loop, the triple A739P, F741T and P742T mutation in peptide C5 converted the peptides’ function from skeletal-like to cardiac-like. The individual A739P mutation, but not F741T or P742T, reduced the functional efficacy of C5. None of the mutations significantly altered the NMR-based secondary structure of the C residues in SDCL (A-P, F-T or P-T). The C5 peptide and its mutants, like the cardiac C5 peptide, were all partially alpha helical at low temperatures. The results show that residue A739 is critical for the functional consequences of interactions between RyR1 and either the skeletal II-III loop or C5, but that none of A739, F741 or P742 are critical determinants of the structure of the C region.

2. INTRODUCTION

The aim of this study was to examine interactions between the II-III loop of the skeletal dihydropyridine receptor (DHPR) L-type Ca2+ channel and skeletal ryanodine receptor (RyR1) channels. The work focuses on the effects of mutations in three key residues in the II-III loop on its structure and function. The DHPR, located in the surface/transverse-tubule membrane, communicates external electrical signals to the RyR Ca2+ release channel in the internal sarcoplasmic reticulum (SR) Ca2+ store. The RyR in cardiac muscle is activated during excitation-contraction (EC) coupling by a Ca2+ influx through the DHPR (1). In contrast in skeletal muscle, the RyR is thought to be activated by a protein-protein interaction with the DHPR. Thus it is of major importance to understand the nature of physical interactions between the skeletal DHPR and RyR. A sequence in the skeletal muscle II-III loop, between the 2nd and 3rd transmembrane repeats of the DHPR, is essential for skeletal type EC coupling (which is independent of Ca2+ influx) (2). Specific residues that are required for skeletal EC coupling have been identified in the “C” region (residues 724-760) of the skeletal II-III loop (3, 4) and are thus thought to be the focus of the physical interaction between the DHPR and RyR. The structure of these important skeletal “C” residues is either random coil at room temperature (5) or
partly helical at low temperatures (6), in marked contrast to the strongly α-helical structure of other regions of the skeletal loop (7, 8). The structure of the cardiac DHPR “C” region is not substantially different from that of the skeletal “C” region (6). The skeletal EC coupling domain has been further localized to residues in the 739–748 region (9). Residues 739, 741 and 742 are different in the cardiac and skeletal DHPR and substitution of the cardiac for skeletal residues interrupts skeletal EC coupling. It was predicted (a) that substitutions at positions 741 and 742 introduced alpha-helical structure into these residues prevented the interaction between the DHPR and RyR (9). However, whole cell measurements of EC can be prevented the interaction between the DHPR and RyR (9).

### Table 1. Synthetic peptides used in this study

<table>
<thead>
<tr>
<th>Peptide C. S.</th>
<th>Peptide C. P.</th>
<th>Peptide C. P.</th>
</tr>
</thead>
<tbody>
<tr>
<td>EFESNVNEVKDPYPSADFPGDDEEDEPEIPVSPRPRP</td>
<td>EFESNVNEVKDPYPSADFPGDDEEDEPEIPVSPRPRP</td>
<td>EFESNVNEVKDPYPSADFPGDDEEDEPEIPVSPRPRP</td>
</tr>
<tr>
<td>EFESNVNEVKDPYPSADFPGDDEEDEPEIPVSPRPRP</td>
<td>EFESNVNEVKDPYPSADFPGDDEEDEPEIPVSPRPRP</td>
<td>EFESNVNEVKDPYPSADFPGDDEEDEPEIPVSPRPRP</td>
</tr>
<tr>
<td>EFESNVNEVKDPYPSADFPGDDEEDEPEIPVSPRPRP</td>
<td>EFESNVNEVKDPYPSADFPGDDEEDEPEIPVSPRPRP</td>
<td>EFESNVNEVKDPYPSADFPGDDEEDEPEIPVSPRPRP</td>
</tr>
<tr>
<td>EFESNVNEVKDPYPSADFPGDDEEDEPEIPVSPRPRP</td>
<td>EFESNVNEVKDPYPSADFPGDDEEDEPEIPVSPRPRP</td>
<td>EFESNVNEVKDPYPSADFPGDDEEDEPEIPVSPRPRP</td>
</tr>
</tbody>
</table>

### 3. MATERIALS AND METHODS

#### 3.1. Materials

The following peptides were synthesised and purified (by the JCSMR Biomolecular Resource Facility) as previously described (7, 14, 16) (Table 1).

#### 3.2. Expression of the DHPR II-III loop

The 391bp or 405bp cDNA fragments, respectively encoding the skeletal (SDCL) and cardiac (CDCL) DHPR II-III loop, were amplified by PCR and cloned in frame down stream of a poly-histidine tagged ubiquitin sequence in the plasmid pHUE (17). Mutations within the “C” region of SDCL, equivalent to those in the Cα peptides (above) were performed to yield SDCL_AFP-PTT, SDCL_AFP, SDCL_F-P and SDCL_P-T respectively, using the Quickchange XL-Site-directed mutagenesis kit (Stratagene). The normal and mutated constructs were checked by sequencing to exclude amplification errors. The plasmid was transfected into E. coli BL21 and expression of fusion protein induced by addition of 0.1 mM isopropyl-beta-D-thiogalactopyranoside to the culture media. The His-tagged protein was purified by chromatography on Ni-agarose (17, 18). Ubiquitin was removed from the N-terminal end of the II-III loop by digestion with a Histagged ubiquitin-dependent protease (17). The ubiquitin protease and cleaved ubiquitin were removed by rechromatography on Ni-agarose. The recombinant II-III loop, without additional residues, was further purified by preparative electrophoresis under native conditions using a Bio Rad model 491 prep cell. The sample was eluted in 25 mM Tris, 192 mM glycine pH 8.3. Uniformly 15N labelled protein was produced by growing the expression strain in M9 minimal media with 15NH4Cl as the sole nitrogen source.

#### 3.3. Single channel measurements

Recording solutions (7, 14, 16) were (mM) (cis): 230 CsCH3O3S, 20 mM CsCl, and 10 N-tris[hydroxymethyl]methyl-2-aminoethanesulfonic acid (TES, pH 7.4 with CsOH) and (trans): 230 CsCH3O3S, 20 CsCl, 1 CaCl2 and 10 TES (pH 7.4). The cis Ca2+ concentration with 10−5 or 10−4 M Ca2+ was buffered using 1 mM BAPTA. The cis chamber was held at ground and the voltage of the trans chamber controlled. Bilayer potential, expressed as V_cis - V_trans, was changed between +40 and −40 mV every 30 s. Two minutes of activity was recorded under control conditions and after each addition of II-III loop or peptide.

#### 3.4. Analysis of channel activity

Currents were analysed over one to two 30 s periods of continuous activity at +40 and −40 mV. Slow fluctuations in the baseline were corrected using an in house baseline-correction program (written by Dr DR Laver). Channel activity was measured either as “mean current” (average of all data points in a record) or as open probability (P_o), using a threshold analysis with the program Channel 2, (developed by PW Gage and M Smith, JCSMR). Measurements of mean current, performed on records from experiments containing 1 to 4 channels,
3.5. Nuclear magnetic resonance (NMR) spectroscopy

The native and mutant Cx peptides were dissolved in 10% D2O/90% H2O to a final concentration of ~2 mM at pH 5.0. The samples for SDCL were prepared in 50 mM potassium phosphate buffer (pH 6.5) containing 10% D2O, with a protein concentration of 1 mM in the presence of 200 mM KCl. All data was recorded at 5°C on a Varian Inova 600 MHz spectrometer equipped with a pentaprobe. In order to obtain resonance assignments one and two dimensional NMR spectroscopy was performed as described previously (7, 16). 13N/1H spectra were acquired using a sensitivity-enhanced 15N-HSQC pulse sequence (19).

3.6. Statistics

The significance of differences between values was tested using a Students T-test, either 1 or 2 sided, for independent or paired data as appropriate or by the non parametric “Sign” test (20). Differences were considered significant when $P \leq 0.05$.

4. RESULTS

4.1. The recombinant native and mutant DHPR II-III loops

The recombinant 126 residue SDCL and 134 residue CDCL, corresponding to the II-III loop of the α1 subunit of the skeletal and cardiac DHPR respectively, were expressed and purified (see Methods) and found to run on SDS-PAGE at the same molecular masses as those shown in (10), i.e. 30 kDa for CDCL and 21 kDa for SDCL (figure 1), which were higher than the calculated weights of 15.23 and 14.13 kDa respectively (6). The four mutant SDCL peptides appear on the SDS-PAGE gel at the same molecular masses as the wild type protein (figure 1).

4.2. Effects of wild type and mutant SDCL on the activity of the skeletal RyR1

The C peptides and recombinant II-III loops were added to the cis solution bathing the cytoplasmic side of native skeletal RyR1 channels. The channels were identified as RyRs by their Cs+ conductance of ~250 pS and their block by 30 microM ruthenium red. The wild type SDCL activated the native channels at concentrations of 10 to 500 nM (figure 2), as previously reported with purified RyR1 channels (10). However in contrast to the purified channels, there was a decline in activity in the native channels with higher peptide concentrations (≥1 microM) indicating that the loop also had a low affinity inhibitory action. The relative Po with 10 microM SDCL was significantly lower than that with 500 nM SDCL (figure 2C). Channel openings increased after perfusion of the cis chamber to dilute SDCL from 10 microM to ~3 nM (figure 2C), indicating a rapid reversal of the low affinity inhibitory action. Both the high affinity activation and low affinity inhibition by SDCL were similar at +40 and -40 mV (figure 2B), indicating that the effects of the recombinant II-III loop were voltage-independent. The current recordings in figure 2A reveal a substantial increase in channel open times and decrease in closed times during activation by SDCL. These changes were observed in all channels and were significant in the average single channel data, with a 1.6-fold increase in open times and a 5-fold decrease in closed times (table 1).

In marked contrast to the wild-type SDCL, addition of the triple mutant SDCLAPFT to the cis solution did not increase channel activity at either +40 or -40 mV (figure 3A & B). Indeed, there was a reversible inhibition which is apparent in the single channel records at ≥10 nM. The average decline in relative Po was significant with 1 microM SDCLAPFT (figure 3C). The reduced channel activity was due to a significant increase in the channel closed times, with essentially no change in open times (table 2). Perfusion of the mutant loop from the cis chamber was accompanied by a rapid increase in activity (figure 3C). The decline in activity, significant only at higher peptide concentrations, and its rapid recovery after washout were reminiscent of the low affinity inhibition seen
Figure 2. Wild type SDCL is a high affinity activator of native skeletal RyR1 channels and causes lower affinity inhibition. (A) shows current recordings from a single RyR1 channel at +40 mV. Channel opening is upward from the closed level (c, solid line) to the maximum single channel current (o, broken line). The channel is activated after 10 nM SDCL is added to its cytoplasmic side and further activated when the [SDCL] is increased to 200 nM. There is a decrease in channel activity when [SDCL] is further increased to 10 microM. (B) – average relative open probability (P_o) as a function of [SDCL] at +40 mV (left) and -40 mV (right). Each point is the average of 4 to 22 experiments. The effect of the loop is the same at positive and negative potentials. (C) - average relative open probability (P_o) from 11 experiments in which the [SDCL] was increased from 10 nM to 10 microM and then perfused from the cis chamber. Average values include data obtained +40 mV and -40 mV. There is a reduction in channel activation at the higher SDCL concentrations and reversal of this inhibitory effect after loop washout. Asterisks in (C) indicate values that are significantly greater than the control. The hatch symbol indicates a significant decline in activity compared with the 500 µM SDCL value.
Table 2. Effects of various SDCL constructs on single RyR1 channel parameters.

<table>
<thead>
<tr>
<th>SDCL</th>
<th>Po reference</th>
<th>Po SDCL</th>
<th>Tc reference</th>
<th>Tc SDCL</th>
<th>Tc reference</th>
<th>Tc SDCL</th>
</tr>
</thead>
<tbody>
<tr>
<td>WT</td>
<td>0.039 +/- 0.013</td>
<td>0.112 +/- 0.033</td>
<td>1.97 +/- 0.18</td>
<td>3.22 +/- 0.77</td>
<td>277 +/- 81</td>
<td>53 +/- 19</td>
</tr>
<tr>
<td>P-T</td>
<td>0.017</td>
<td>0.055</td>
<td>2.04</td>
<td>2.56</td>
<td>491</td>
<td>114</td>
</tr>
<tr>
<td>F-T</td>
<td>0.031 +/- 0.01</td>
<td>0.015 +/- 0.005</td>
<td>3.27 +/- 0.44</td>
<td>2.99 +/- 0.31</td>
<td>318 +/- 92</td>
<td>474 +/- 122</td>
</tr>
<tr>
<td>AFP-PTT</td>
<td>0.143 +/- 0.047</td>
<td>0.051 +/- 0.018</td>
<td>3.88 +/- 0.89</td>
<td>3.67 +/- 0.91</td>
<td>51.9 +/- 17.2</td>
<td>195 +/- 78</td>
</tr>
</tbody>
</table>

Single channel parameters recorded before (reference) and after (SDCL) adding 1 microM of the wild type (SDCL_WT) and mutant SDCL to bilayers in which a single RyR1 channel was active. N is the number of experiments. The number of observations (in parentheses) is double the number of experiments because data at +40 and -40 mV were included in the averages. Asterisks indicate significant changes induced by SDCL.

Figure 3. The triple mutant SDCL/AFP-PTT does not activate native RyR1, but does inhibit the channels. (A) & (B) show 3 s current recordings from a single RyR1 channel at +40 and -40 mV respectively. The channel opens from the closed level (c, solid line) to the maximum single channel current (o, broken line). The 1st trace in each panel shows control data, the 2nd trace after adding 100 nM SDCL/AFP-PTT to the cis chamber and the 3rd trace after increasing the concentration to 1 microM. The numbers to the right of each trace show Po for a 30 s recording under each condition. Channel activity decreases as the peptide concentration is increased at both potentials. (C) – comparison of average relative open probability (Po) (combined +40 and -40 mV data) for 11 experiments with wild type SDCL (filled bins – data from figure 2 included for comparison) and 8 experiments with SDCL/AFP-PTT (hatched bins). The relative Po with the mutant loop is significantly less than that with the wild-type loop during exposure and after washout, indicated by asterisks. (D) – average relative Po with SDCL/AFP-PTT (hatched bins) displayed with an expanded vertical axis to display inhibition by the mutant loop. The asterisks in (C) indicate a significant difference between the mutant and wild-type data, while the asterisk in (D) indicates a significant decline from control with 1 microM SDCL/AFP-PTT and the cross-hatch indicates a significant recovery after washout of the loop.
Functional and structural significance of DHPR residues

with the native peptide. Thus the triple mutation appeared to abolish the high affinity activating effect of SDCL, while leaving the low affinity inhibitory effect intact.

To determine whether all three cardiac residues were required for the functional difference between SDCL and SDCL$_{AFP-PTT}$, we substituted each of the residues individually. Substitution of the threonine for phenylalanine to position 741 (SDCL$_{F-T}$) or threonine for proline at position 742 (SDCL$_{P-T}$) had little effect on the activating ability of SDCL. The records in figure 4A show that the single channel openings were more frequent and longer with SDCL$_{P-T}$, with an increase in $P_0$ from 0.07 to 0.12. The mean current in the multiple channel experiment shown in figure 4B increased >3-fold after addition of SDCL$_{P-T}$ with one channel open in the bilayer under control conditions and 3 channels open with the mutant loop. As with the wild type protein, activation by the SDCL$_{P-T}$ was due to changes in both open and closed times, although in this case the increase in average open time alone was significant (table 1). Only one of 5 experiments with SDCL$_{P-T}$ was a single channel experiment and in that case the open times also increased and closed times fell (table 1). The changes in channel gating were similar with all three activating loop peptides, with the relative decrease in closed times being considerably greater than the relative increase in open times (table 1).

Unlike the F-T and P-T substitutions, substitution of a proline for the alanine at position 739 (SDCL$_{A-P}$) changed the effect of the loop on the RyR1 channels from activation to inhibition, in the same way as the triple mutation. The decline in channel activity was similar at both positive and negative potentials in the experiment in figure 5A&B and in 9 other experiments. The decline in average relative $P_0$ was significant at all concentrations of SDCL$_{A-P}$ tested (10 nM to 1 microM, figure 5C) and, like the inhibition with SDCL$_{AFP-PTT}$, was due to a significant increase in closed durations with essentially no change in the mean open time (table 1). Also similar to the action of SDCL$_{AFP-PTT}$, was the immediate increase in activity when the A-P mutant was washed out of the cis chamber in 11 of 14 cases (a significant increase according to the non-parametric sign test) (figure 5C). These results show that the A-P substitution alone was sufficient to remove activation and to unmask the full inhibitory action of SDCL.

Since the AFP-PTT or A-P substitutions inserted cardiac residues into the skeletal sequence, it was of interest to see whether the effect of any of the mutant SDCL peptides mimicked the effect of the cardiac loop (CDCL) on RyR1. The results in figure 6A show that CDCL, like SDCL, increased native RyR1 activity, although the increase in relative $P_0$ was significantly less with CDCL. Analysis of the one single channel experiment in this series showed that there was no change in open times and a 50% decline in closed times. This activation was also similar to, but less than, that with SDCL$_{F-T}$ or SDCL$_{P-T}$ and in marked contrast to the inhibitory effects of SDCL$_{AFP-PTT}$ and SDCL$_{A-P}$. Washout activation upon removal of CDCL was seen in only one of 4 observations, suggesting that inhibitory effect of CDCL may be weaker than that of SDCL. Together, the results show that the mutations do not result in cardiac like loop activity. The F-T and P-T substitutions do not depress activation to the level seen with CDCL, while the AFP-PTT and A-P substitutions produce mutants with activity unlike that seen with either the wild type skeletal and cardiac loops.

In conclusion, the A-P substitution in the cardiac loop changed the action of SDCL from excitatory to inhibitory, however the presence of the proline residue in CDCL did not render the cardiac loop inhibitory although CDCL produced significantly less activation of RyR1 than the skeletal loop. This results suggests that activation by the loop depends either (a) on binding more than one set of loop residues, so that the functional effects of “C” region binding are masked by effects of the binding of other regions in CDCL, but not in SDCL or (b) more generally, that the functional effects of the proline residue are negated/reversed by other non-conserved regions/residues in CDCL.

4.3. Effects of the mutant $C_S$ peptides on skeletal RyR1
The effects of the same substitutions in the 36 residue peptide $C_S$ (the skeletal $C$ sequence, see Methods) were examined. The wildtype $C_S$ activates skeletal RyRs at concentrations of 10 nM to 10 microM (5, 21). The triple mutant $C_{SFP-PTT}$ also activated skeletal RyRs, although at a peptide concentration of 100 nM, the ~1.9-fold activation by the mutant peptide was significantly less than the ~4.4-fold activation by the wild-type peptide (Figure 6B). Indeed, activation by the triple mutant at 100 nM was not significantly different from the ~1.5-fold activation of skeletal RyRs produced by the cardiac $C$ peptide, $C_C$ (Figure 6B and (21)). Thus the activation of RyR1 by $C_{SFP-PTT}$ appeared to be more like that of $C_C$ than $C_S$.

4.4. The mutant $C_S$ peptide activates cardiac RyR2 channels
Cardiac channels provided a better functional probe for the different $C$ peptides than RyR1 because the skeletal $C_S$ peptide inhibits the channel, while the cardiac $C_C$ peptide activates the channel, even though both peptides act at the same site on RyR2 (6). The results in figure 6C show that $C_{SFP-PTT}$ strongly activated RyR2 in a very similar manner to peptide $C_C$. Therefore the triple mutation also converted the action of the peptide on RyR2 from a skeletal-like to cardiac-like. Examination of the three individual $C_S$ mutants showed that, in contrast to the full loop, none of the single substitutions were as effective as the triple substitution in changing the effect of the peptide from inhibition to activation. However, the ability of the A-P mutant to inhibit RyR2 was significantly less than that of the wildtype $C_S$ or the P-T or F-T mutants (figure 6D). Although activation was not seen in the average $C_{SA-P}$ data, it was seen in 2 of the 5 experiments. In contrast to $C_{SA-P}$, all channels were inhibited in experiments in which $C_{SF-P}$ and $C_{SP-P}$ were added to the cytoplasmic solution. As with the full loop, the results again point to a critical role of an alanine at position 739 in determining the function of the $C$ region of the skeletal II-III loop.
Functional and structural significance of DHPR residues

Figure 4. Individual mutants SDCL_{F-T} and SDCL_{P-T} activate RyR1 in a similar manner to the wild type SDCL. (A) and (B) show 3 s current recordings +40 mV with channel opening from the closed level (c, solid line) to the maximum single channel current (o, broken line in (A)) or the maximum current for the 3 RyR channels (o, broken line in (B)). A single RyR channel exposed to SDCL_{F-T} is shown in (A) and current from a bilayer containing 3 channels after exposure to SDCL_{P-T} is shown in (B). The 1st trace in each panel shows control data, the 2nd trace after adding 10 nM loop to the cis chamber and the 3rd trace after increasing the concentration to 100 nM. The numbers to the right of each trace show P_0 in (A) or I’ (mean current) in (B) for a 30 s recording under each condition. (C) and (D) show average relative open probability (P_0) (combined +40 and -40 mV data) for 11 experiments with wild type SDCL (filled bins) and 5 experiments with SDCL_{P-T} (hatched bins in (C)) and 10 experiments with SDCL_{F-T} (hatched bins in (D)). Data for the wild type SDCL (from figure 2) is included for comparison (filled bins). Asterisks in (C) and (D) indicate values that are significantly greater than control.
Functional and structural significance of DHPR residues

Figure 5. The single mutation in SDCL_{A-P} prevents the activation of native RyR1 channels by the recombinant loop, but does not prevent inhibition. (A) & (B) show 3 s current recordings from a single RyR1 channel at +40 and -40 mV respectively. The channel opens from the closed level (c, solid line) to the maximum single channel current (o, broken line). The 1st trace in each panel shows control data, the 2nd trace after adding 100 nM SDCL_{A-P} to the cis chamber and the 3rd trace after increasing the concentration to 1 microM. The numbers to the right of each trace show P_{o} for a 30 s recording under each condition. Channel activity decreases as the peptide concentration is increased at both potentials. (C) – comparison of average relative open probability (P_{o}) (combined +40 and -40 mV data) for 11 experiments with wild type SDCL (filled bins – data from figure 2 included for comparison) and 10 experiments with SDCL_{A-P} (hatched bins). The relative P_{o} with the mutant loop is significantly less than that with the wild-type loop during exposure to SDCL_{A-P}. (D) – average relative P_{o} with SDCL_{A-P} (hatched bins) displayed with an expanded vertical axis to display inhibition by the mutant loop. The asterisks in (C) indicate significant differences between the wild-type and mutant data, while the asterisks in (D) indicate a significant decline from control with all SDCL_{A-P} concentrations.
Figure 6. Activity of the wild type cardiac DHPR II-III loop (CDCL) and the mutant Cs peptides. Average relative open probability ($P_0$), shown as a function of loop (or peptide) concentration, includes data at +40 and -40 mV. (A) shows a comparison of the effects of CDCL (filled bins, N = 5 experiments) and SDCL (hatched bins, N = 11) on skeletal RyR1 channels. There is a significant increase in activity with CDCL, but it is significantly less than that with SDCL. (B) shows the effects of CsAFP-PTT on RyR1 (N = 5 experiments, filled circles). The data at 100 nM is compared with the effects of CC (narrow-hatched bin) and Cs (wide-hatched bin) on RyR1 (21). (C) shows the effects of CsAFP-PTT on RyR2 (N = 6 experiments, filled circles). The data is compared with the effects of the wild type Cc (activation, upper broken line) and Cs (inhibition, lower broken line) on RyR2 from (6). (D) compares the effects of CsAFP (N = 5 experiments, filled bins), CsF-T (N = 5 experiments, narrow-hatched bins) and CsP-T (N = 4 experiments, wide-hatched bins) on RyR2 channels. The asterisks indicate significant differences between the control and test data.
Functional and structural significance of DHPR residues

4.5. Structure of the Mutant CS peptides

We have previously shown with 1H NMR that both the CS and CC peptides have the ability to form weak, partially structured alpha helices when examined at low temperatures (6). This evidence was obtained from the NH-NH connectivities in NOESY spectra which indicate that the residues are close in space and likely to adopt an alpha-helical structure. There are however minor structural differences between these peptides including a more structured N-terminal region for CS and a marginally more extended alpha-helix toward the conserved clustered negatively charged region of CC (figure 7 and (6)). The results of NMR analysis of the four mutant CS peptides are also shown in figure 7. The triple AFP-PTT mutation reduced the nascent helix in the region of the mutated residues (consistent with P-TT being less helical than A-FP in the native cardiac and skeletal peptides respectively), but had no effect the helical nature of the downstream conserved negatively charged residues (figure 7). The A-P mutant is slightly less helical around the mutation site, as is the P-T mutant, when compared with wild type CS. The secondary structure profile of the F-T mutant is not significantly different from the wild type CS. No structural changes were observed between the N-terminal helical segment (SNVNE) in any of the mutants. It should be noted that various amino acids have different tendencies to form α-helices. Alanine has the greatest ability to stabilise an alpha-helix, while proline (lacking an amide hydrogen) is least likely to do so (22). However, all NOE evidence points to a very weak helical structure in residues 739-742 in both the presence and absence of the prolines with the individual substitutions.

In an attempt to determine whether the mutations resulted in any gross conformational differences in SDCL, we compared the chemical shift profile of the 15N labelled wild type SDCL and SDCL_{AFP,PTT} using 15N/1H spectra (not shown). NMR chemical shifts are dependent on the environment of the nuclei and are highly sensitive to structural and environmental perturbations. Apart from the mutated residues as well as their adjacent neighbours, only minor or no differences were observed in other regions including the cluster of negatively charged residues downstream from the mutations.

The conclusion from these mutation studies is that residue 739 is important in determining the functional activity of the skeletal II-III loop and C peptide, but none of residues 739-742 have a pronounced impact on the overall structural profile of the C region of the skeletal loop. We do not find any evidence for (i) individual mutations increasing the helical structure in the conserved cluster of negatively charged residues or (ii) that interactions with the RyR are reduced by helical content in the negatively charged residues.

5. DISCUSSION

This study provides the first molecular data on the consequences of mutations in the “C” region of the skeletal DHPR II-III loop on interactions between the II-III loop and the skeletal RyR and on the structure of the “C” region. The effects of substitution of cardiac residues for A739, F741 and P742 in the 126 residue skeletal DHPR II-III loop (SDCL) on its functional interactions with the skeletal muscle RyR1 have been examined. The structural and functional effects of the same mutations in a 37 residue skeletal “C” region peptide, CS are compared with the effects on the longer SDCL sequence. The mutations did not prevent interactions between the loop and the RyR, but the A-P substitution altered the functional consequences of the interactions. Novel observations were that (a) SDCL exerts high affinity activation and lower affinity inhibition on native RyR1 channels, (b) a single skeletal DHPR
Functional and structural significance of DHPR residues

Figure 8. A model showing hypothetical interactions between the skeletal or cardiac DHPR II-III loop and RyR1. Interactions between the C region of SDCL and RyR1 strongly activate the channel (indicated by the green cone), while interactions between the C region in CDCL and RyR1 weakly activates the channel. A second region (X) in SDCL inhibits RyR1 (indicated by the red cone) or, in CDCL activates the channel. The channel is inhibited when inhibition is stronger than activation as with SDCL<sub>A-P</sub>. residue, A739, is responsible for the excitatory action of the skeletal loop and its substitution for a proline rendered the loop inhibitory. (c) the mutations in peptide C<sub>S</sub> also profoundly altered the ability of the peptide to activate RyRs and (d) the substitutions did not significantly alter the structure of the C residues. Although some of the altered interactions with RyR1 are consistent with changes in EC coupling following similar mutations in the DHPR in myocytes (9), the results suggest that changes in EC coupling may also depend on micro-targeting of DHPRs and RyRs since they do not abolish the interaction with the RyR or alter the secondary structure of the “C” residues.

5.1. Dual actions of both SDCL and CDCL on native skeletal RyRs

Both recombinant DHPR II-III loops bind to and activate purified RyR1, with CDCL being more active (10, 23). Both loops also bound to the native RyR1 with high affinity in the present study, although activation by CDCL was less than that by SDCL. In addition to the high affinity slowly reversible activation, SDCL also induced a lower affinity rapidly reversible inhibition of the native RyR1. The A739P substitution in SDCL<sub>A-P</sub> and SDCL<sub>A-P</sub> prevented its activation of RyR1, but not its inhibitory effects. This selective removal of activation, and the different affinities and reversibility of activation and inhibition suggest that SDCL interacts with two separate sites on RyR1. The presence of two interaction sites is also suggested by the fact that the same substitutions in the 35 residue peptide C<sub>S</sub> reduce its ability to activate RyR1, but did not render the peptide inhibitory. This effect on the C region could underlie the reduced activation by SDCL<sub>A-P</sub> and SDCL<sub>A-P</sub>, but not the inhibitory action of these two mutant loops.

The observations can be reconciled by a model in which SDCL binds to RyR1 through two sites, inducing activation at one and inhibition at the other (figure 8). It is assumed that the C region binds to the activation site (see Discussion below). The substitutions in SDCL<sub>A-P</sub> and SDCL<sub>A-P</sub> reduce the loops activating ability by removing the alanine residue at position 739. The effect of the mutants on RyR activity is inhibitory because the interaction with the second site is retained. The hypothesis can be extended to include the actions of CDCL with the further assumptions (a) that activation of RyR1 by the C region in CDCL is less than activation by the C region in SDCL (because there is no alanine in the position equivalent to 739 in CDCL) and (b) that the effect of the binding of the second region is to cause relatively weaker inhibition or weak activation. This final assumption is consistent with the reduced washout activation with CDCL. This hypothesis reconciles the fact that the triple mutation in CDCL<sub>A-P</sub> converts the function of the C<sub>S</sub> peptide from skeletal-like to cardiac-like, but the same mutation in SDCL<sub>A-P</sub> does not result in cardiac-like loop activity.

It is assumed that the loop interacts with the RyR through the C region because the isolated C residues modify channel activity (Introduction and Results), mutations in the C region alter interactions between the II-III loop and RyR1 (this study), and alter EC coupling (9). Competition studies suggest that the C region is also involved in CDCL binding to RyR2 (6). The second interaction site could be the A region (residues 671-690). Deletion and competition studies suggest that the A region in II-III loop interacts with RyR1 (6, 10, 23, 24). The high affinity interaction between RyR1 and peptide A activates the channel (Introduction) in contrast to the inhibitory effect postulated in the model outlined above. However A peptides have the potential to inhibit RyR<sub>1</sub>. Activation of RyR1 by A and related peptides is reduced when cis [Ca<sup>2+</sup>] is >10 microM (unpublished and (25)), while the peptides inhibit RyR2 when cis [Ca<sup>2+</sup>] is activating (26). The effects on RyR2 are relevant because the actions of A and related peptides are not RyR isoform specific (26, 27) and responses of RyR2 are likely to reveal responses that could occur in RyR1.

5.2. Changes in the function of the C<sub>S</sub> peptides were not correlated with structural changes

We have previously shown that there is little isoform specificity in the structure of the C<sub>E</sub> and C<sub>S</sub> (6).
Neither of the peptides had a strong alpha-helical structure such as that found in the A or the B regions (8, 16). Structural analysis in this study revealed only small differences between the structures of the wild type C5 and the mutant peptides. Weak nascent helices involving the C residues were in fact weaker in the C_{SAF-P} and C_{SAP} mutants whose actions most closely resembled C_{C} peptide (6). Thus the changes in activity were related to the A-P substitution rather than to any consistent change in helical content. The predicted increase in helical structure in the II-III loop did not alter the effects of (DDEED) residues downstream from the ADPF sequence with 2 of the 3 individual mutations (9) was not seen in our structural analysis of either the C peptides or of SDCL. There was a similar nascent helical structure in the DDEED region in the wildtype C5 and SDCL and in all mutants. The helical content in the DDEED residues was marginally less in C_{SP}-\text{T} than in the other mutant peptides.

It is worth noting that our structural determinations with SDCL indicate that the structures of the A, B and C regions in the full skeletal II-III loop are very similar to the structures of shorter peptides with sequences corresponding to each region (unpublished observations). It likely that the secondary structure will also be retained in the in vitro situation, even though the exact tertiary structure may vary. It is also likely that the secondary structures of the mutants determined here (figure 7) will be analogous to those in the wildtype peptide/protein. The results from this study indicate that there are no gross structural changes induced by the mutations in these peptide fragments which would affect the recognition of the RyR binding partner. However the amino acid substitution per se could affect recognition of the binding partner if the substituted amino acid was directly implicated in binding or the tertiary structure of the protein. An example of this was seen with the AB region of the II-III loop where the mutation of some residues resulted in a dramatic change in activity without altering the alpha helical secondary structure (8).

5.3. Comparison with whole cell studies

Individual A739P, F741T, P742T and D744E substitutions in the DHPR each disrupt skeletal EC coupling and it has been suggested that the residues are vital for an interaction with the RyR (9). Our results show that the A739P substitution alters, but does not prevent, the physical interaction between the RyR and either the full SDCL or C peptide. The individual F741T and P742T substitutions did not alter the effects of the II-III loop on the RyR. It is notable that the A739P mutation in whole cells altered EC coupling in a manner that was qualitatively different from that of the other mutations. Our results suggest that the F741T and P742T mutations must alter EC coupling in the whole cell by changing some parameter other than the ability of the DHPR and RyR to interact with each other. The mutations could, for example, alter the targeting of the proteins into positions that would allow them to physically interact. Such targeting could include the formation of tetrads or the precise alignment of tetrads with the RyR protein. Inappropriate targeting at this molecular level could well disrupt EC coupling but would not be detected with fluorescence microscopy. Another possibility that cannot be discounted is that the F741T and P742T mutations may alter the tertiary structure of the skeletal II-III loop in the in vivo situation in a manner that differs from the effects on the structure of the isolated SDCL. The unavoidable conclusion from both our study and that of (9) is that interactions between the DHPR and RyR in vivo and in vitro are critically dependent on residues 739-742 in the skeletal sequence.

In summary, we show that introduction of a cardiac residue into position 739 of the skeletal DHPR II-III loop prevents the loop from activating the RyR in isolated systems. There is a strong correlation between the in vitro observation that residue 739 influences molecular interactions between the two proteins and in vivo measurements of EC coupling (9). The in vitro study of the ability of the two molecules to interact suggests that mutations in neighbouring residues 740-742 do not prevent a physical association between the C region and the RyR but may alter the micro-targeting of the DHPR and RyR in whole cells. In contrast to the changes in helical content that were predicted by (9), we find that there is no significant change in structure as a result of the mutations.

6. ACKNOWLEDGEMENTS

The authors are grateful to Suzy Pace and to Joan Stivala for assistance with preparation and characterisation of SR vesicles, to Sarah Watson for assistance with some of the single channel studies. We thank Professor Gerhard Meissner for providing us with cDNA for SDCL and CDCL. The project was supported by a grant from the Australian National Health and Medical Research Council # 224235.

7. REFERENCES


11. Stange, M., A. Tripathy and G. Meissner: Two domains in dihydropyridine receptor activate the skeletal muscle Ca\(^{2+}\) release channel. *Biophys J* 81, 1419-29 (2001)


Functional and structural significance of DHPR residues

Footnote 1: Two types of inhibition are exerted by the A peptides. The one referred to here is seen with 10 – 100 nM peptide, is Ca\textsuperscript{2+}-dependent and voltage-independent (6). The other is a channel block seen only at +40 mV in symmetrical solutions and only with >1 microM peptide (1).

Key Words: Dihydropyridine receptor, Ryanodine receptor, Protein, protein interactions

Send correspondence to: Dr A F Dulhunty, PO Box 334, Canberra, ACT 2601, Australia, Tel: 61-2-6125-4491, Fax: 61-2-6125-4761, E-mail: angela.dulhunty@anu.edu.au

http://www.bioscience.org/current/vol10.htm